Literature DB >> 19135090

Using high-throughput genomics to study hepatitis C: what determines the outcome of infection?

Kathie-Anne Walters1, Michael G Katze.   

Abstract

High-throughput genomic methods are now being used to study a wide variety of viral diseases, in an effort to understand how host responses to infection can lead either to efficient elimination of the pathogen or the development of severe disease. This article reviews how gene expression studies are addressing important clinical issues related to hepatitis C virus infection, in which some 15-25% of infected individuals are able to clear the virus without treatment, while the remainder progress to chronic liver disease that can lead to cirrhosis and death. Similar methods are also being used in an effort to identify the mechanisms underlying the failure of some hepatitis C patients to respond to interferon-alpha/ribavirin therapy. By providing a detailed picture of virus-host interactions, high-throughput genomics could potentially lead to the identification of novel cellular targets for the treatment of hepatitis C.

Entities:  

Mesh:

Year:  2009        PMID: 19135090      PMCID: PMC2683667          DOI: 10.1016/j.antiviral.2008.12.005

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  85 in total

Review 1.  Viral determinants of resistance to treatment in patients with hepatitis C.

Authors:  Anette Wohnsland; Wolf Peter Hofmann; Christoph Sarrazin
Journal:  Clin Microbiol Rev       Date:  2007-01       Impact factor: 26.132

2.  Defective hepatic response to interferon and activation of suppressor of cytokine signaling 3 in chronic hepatitis C.

Authors:  Ying Huang; Jordan J Feld; Ronda K Sapp; Santosh Nanda; Jiing-Huey Lin; Lawrence M Blatt; Michael W Fried; Krishna Murthy; T Jake Liang
Journal:  Gastroenterology       Date:  2006-11-29       Impact factor: 22.682

3.  A functional SNP of interferon-gamma gene is important for interferon-alpha-induced and spontaneous recovery from hepatitis C virus infection.

Authors:  Ying Huang; Huiying Yang; Brian B Borg; Xiaowen Su; Shannon L Rhodes; Kai Yang; Xiaomei Tong; George Tang; Charles D Howell; Hugo R Rosen; Chloe L Thio; David L Thomas; Harvey J Alter; Ronda K Sapp; T Jake Liang
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-10       Impact factor: 11.205

4.  Identification of a specific gene expression pattern associated with HCV-induced pathogenesis in HCV- and HCV/HIV-infected individuals.

Authors:  Kathie-Anne Walters; Maria W Smith; Sampa Pal; Jill C Thompson; Matthew J Thomas; Matthew M Yeh; David L Thomas; Matthew Fitzgibbon; Sean Proll; Nelson Fausto; David R Gretch; Robert L Carithers; Margaret C Shuhart; Michael G Katze
Journal:  Virology       Date:  2006-03-30       Impact factor: 3.616

5.  Silencing of USP18 potentiates the antiviral activity of interferon against hepatitis C virus infection.

Authors:  Glenn Randall; Limin Chen; Maryline Panis; Andrew K Fischer; Brett D Lindenbach; Jing Sun; Jenny Heathcote; Charles M Rice; Aled M Edwards; Ian D McGilvray
Journal:  Gastroenterology       Date:  2006-08-22       Impact factor: 22.682

6.  Genomic analysis of increased host immune and cell death responses induced by 1918 influenza virus.

Authors:  John C Kash; Terrence M Tumpey; Sean C Proll; Victoria Carter; Olivia Perwitasari; Matthew J Thomas; Christopher F Basler; Peter Palese; Jeffery K Taubenberger; Adolfo García-Sastre; David E Swayne; Michael G Katze
Journal:  Nature       Date:  2006-09-27       Impact factor: 49.962

7.  Aberrant innate immune response in lethal infection of macaques with the 1918 influenza virus.

Authors:  Darwyn Kobasa; Steven M Jones; Kyoko Shinya; John C Kash; John Copps; Hideki Ebihara; Yasuko Hatta; Jin Hyun Kim; Peter Halfmann; Masato Hatta; Friederike Feldmann; Judie B Alimonti; Lisa Fernando; Yan Li; Michael G Katze; Heinz Feldmann; Yoshihiro Kawaoka
Journal:  Nature       Date:  2007-01-18       Impact factor: 49.962

Review 8.  Epidemiology of hepatitis C virus infection.

Authors:  Miriam J Alter
Journal:  World J Gastroenterol       Date:  2007-05-07       Impact factor: 5.742

Review 9.  Chronic infections with hepatotropic viruses: mechanisms of impairment of cellular immune responses.

Authors:  Barbara Rehermann
Journal:  Semin Liver Dis       Date:  2007-05       Impact factor: 6.115

10.  Distinct cellular responses differentiating alcohol- and hepatitis C virus-induced liver cirrhosis.

Authors:  Sharon L Lederer; Kathie-Anne Walters; Sean Proll; Bryan Paeper; Shahar Robinzon; Loreto Boix; Nelson Fausto; Jordi Bruix; Michael G Katze
Journal:  Virol J       Date:  2006-11-22       Impact factor: 4.099

View more
  6 in total

1.  A novel microRNA boosts hyper-β-oxidation of fatty acids in liver by impeding CEP350-mediated sequestration of PPARα and thus restricts chronic hepatitis C.

Authors:  Suchandrima Ghosh; Joyeeta Chakraborty; Avijit Goswami; Sayantani Bhowmik; Susree Roy; Amit Ghosh; Sakshi Dokania; Priyanka Kumari; Simanti Datta; Abhijit Chowdhury; Suvendra Nath Bhattacharyya; Raghunath Chatterjee; Soma Banerjee
Journal:  RNA Biol       Date:  2020-06-07       Impact factor: 4.652

2.  Proteome and computational analyses reveal new insights into the mechanisms of hepatitis C virus-mediated liver disease posttransplantation.

Authors:  Deborah L Diamond; Alexei L Krasnoselsky; Kristin E Burnum; Matthew E Monroe; Bobbie-Jo Webb-Robertson; Jason E McDermott; Matthew M Yeh; Jose Felipe Golib Dzib; Nathan Susnow; Susan Strom; Sean C Proll; Sarah E Belisle; David E Purdy; Angela L Rasmussen; Kathie-Anne Walters; Jon M Jacobs; Marina A Gritsenko; David G Camp; Renuka Bhattacharya; James D Perkins; Robert L Carithers; Iris W Liou; Anne M Larson; Arndt Benecke; Katrina M Waters; Richard D Smith; Michael G Katze
Journal:  Hepatology       Date:  2012-04-24       Impact factor: 17.425

3.  Genomics and proteomics in liver fibrosis and cirrhosis.

Authors:  Rebekka A Hannivoort; Virginia Hernandez-Gea; Scott L Friedman
Journal:  Fibrogenesis Tissue Repair       Date:  2012-01-03

4.  Individualized treatment of chronic hepatitis C with pegylated interferon and ribavirin.

Authors:  Roberto J Carvalho-Filho; Olav Dalgard
Journal:  Pharmgenomics Pers Med       Date:  2010-03-11

Review 5.  Applications of high-throughput genomics to antiviral research: evasion of antiviral responses and activation of inflammation during fulminant RNA virus infection.

Authors:  John C Kash
Journal:  Antiviral Res       Date:  2009-04-16       Impact factor: 5.970

6.  ADAR1 polymorphisms are related to severity of liver fibrosis in HIV/HCV-coinfected patients.

Authors:  Luz M Medrano; Juan Berenguer; María A Jiménez-Sousa; Teresa Aldámiz-Echevarria; Francisco Tejerina; Cristina Diez; Lorena Vigón; Amanda Fernández-Rodríguez; Salvador Resino
Journal:  Sci Rep       Date:  2017-10-10       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.